Morocco Unveils Locally Developed Cannabis-Based Medicine for Severe Epilepsy

Morocco has marked a significant milestone in its pharmaceutical industry with the introduction of its first locally manufactured cannabis-based medicine. Developed by Pharma 5, the medication, called Cannabidiol Pharma 5, is designed to treat certain severe forms of epilepsy that do not respond well to conventional treatments. The project, which took five years of research, involved Moroccan researchers, laboratories, and industrial expertise, with an investment exceeding 200 million dirhams.

The cannabis-based medicine is derived from cannabidiol, better known as CBD, purified to more than 98%. Pharma 5 has also developed a locally produced active pharmaceutical ingredient from cannabis. The medication has been available in Morocco since November 9, following regulatory approval. It is a regulated prescription medicine intended for specific medical conditions, not recreational cannabis or a product for general wellness.

The launch of Cannabidiol Pharma 5 represents a major step for Moroccan pharmaceutical production. The project brings together research, agriculture, and industry, from regulated cannabis cultivation to the final medicine. This achievement showcases locally developed medical technology and its potential to create opportunities beyond traditional pharmaceutical manufacturing.

However, affordability remains a challenge for the new medicine. A 100 ml bottle costs approximately 5,498 dirhams, with reimbursement approval still being processed. This price makes access an important part of the conversation, particularly for families dealing with serious medical conditions.

The development of Cannabidiol Pharma 5 is an achievement for Moroccan science, demonstrating the country's capability in producing high-quality, regulated medicines. The next challenge will be ensuring that patients who need this treatment can actually access it.

Pharma 5's locally produced active pharmaceutical ingredient and cannabis-based medicine have the potential to make a significant impact on the treatment of severe epilepsy in Morocco. The company's investment and expertise have resulted in a product that meets the needs of patients with limited treatment options.

As Morocco continues to develop its pharmaceutical industry, the launch of Cannabidiol Pharma 5 serves as a promising example of the country's potential in producing innovative, locally developed medical solutions. The focus now shifts to making this treatment accessible to those who need it, addressing concerns around affordability and reimbursement.

Key points

• The medicine, called Cannabidiol Pharma 5, has been available in Morocco since November 9, following regulatory approval.
• A 100 ml bottle costs approximately 5,498 dirhams, with reimbursement approval still being processed.
• The project involved Moroccan researchers, laboratories and industrial expertise, with an investment exceeding 200 million dirhams.